Daily Wire/Andrew Klavan: Poison Ivy, X22 Report, BCP/N.B.T.N., Dan Bongino, RAVries | EP1041
Rumble
Daily News Update - https://murtech.com/
Wire
News and Video Search Results
News coverage
-
Innate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Patients With Sézary Syndrome at ASH 2023
Business Wire
-
How The Federal-Private Speech Police Operated In Election 2020: With Radar Highly Attuned To The Right
Upworthy
-
Belgian, Port Houston and Partners Sign Memorandum of Understanding on Energy Transition Cooperation
Business Wire
-
Marstacimab Phase 3 Data Presented at ASH 2023 Demonstrate Significant Bleed Reduction in Hemophilia A and B
Business Wire
0 shares
1 views
You might like
Wire media coverage
Orca Bio Presents Positive Data Demonstrating the Potential for Orca-T and Orca-Q to Expand Treatment to Additional Patient Groups at the 65th ASH Annual Meeting
Business Wire
MENLO PARK, Calif.--(BUSINESS WIRE)--Orca Bio announced positive new data presented at the 65th American Society of Hematology..
-
Bristol Myers Squibb Presents Primary Efficacy and Safety Analysis of the Phase 3 COMMANDS Trial of Reblozyl for Treatment of Anemia in Erythropoiesis Stimulating Agent-Naïve Patients with Lower-Risk Myelodysplastic Syndromes at ASH 2023
Business Wire
-
LPSN INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that LivePerson, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Business Wire
-
Scenic Biotech Announces Positive Preclinical Data for its QPCTL Inhibitor SC-2882 as Potential New Therapeutic Approach for Diffuse Large B-Cell Lymphoma
Business Wire
-
Port Houston Regular Commission Meeting
Business Wire
Advertisement
More coverage
Morning Java S4 Ep3 - 6 suspicious wire transfers using Biden's address
Rumble
Banks report 6 suspicious wire transfers using Biden's address. Why hasn't there been impeachment hearings?..
-
Rallybio Presents Natural History Study for Fetal and Neonatal Alloimmune Thrombocytopenia at the 65th American Society of Hematology Annual Meeting
Business Wire
-
New Pivotal Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma (FL)
Business Wire
-
Long-term Follow-up Data From bluebird’s Gene Therapy Program in Sickle Cell Disease Support Durable, Potentially Curative Benefits Through Stable Production of Anti-Sickling Adult Hemoglobin and Resolution of Vaso-Occlusive Events
Business Wire
-
New Data Reinforce the Benefit of Early Preventative Treatment With Genentech’s Hemlibra (emicizumab-kxwh) for Babies With Severe hemophilia A
Business Wire